Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

ClinicalTrials.gov ID: NCT05110157

Public ClinicalTrials.gov record NCT05110157. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

Study identification

NCT ID
NCT05110157
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
442 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 28, 2021
Primary completion
Feb 3, 2025
Completion
Feb 17, 2025
Last update posted
Feb 9, 2026

2021 – 2025

United States locations

U.S. sites
50
U.S. states
15
U.S. cities
42
Facility City State ZIP Site status
Neurocrine Clinical Site Phoenix Arizona 85012
Neurocrine Clinical Site Rogers Arkansas 72758
Neurocrine Clinical Site Anaheim California 92805
Neurocrine Clinical Site Bellflower California 90706
Neurocrine Clinical Site Culver City California 90230
Neurocrine Clinical Site Garden Grove California 92845
Neurocrine Clinical Site Lemon Grove California 91945
Neurocrine Clinical Site Long Beach California 90807
Neurocrine Clinical Site Oceanside California 92056
Neurocrine Clinical Site Pico Rivera California 90660
Neurocrine Clinical Site Riverside California 92506
Neurocrine Clinical Site San Diego California 92102
Neurocrine Clinical Site San Diego California 92103
Neurocrine Clinical Site San Jose California 95124
Neurocrine Clinical Site Santa Ana California 92705
Neurocrine Clinical Site Stanford California 94305
Neurocrine Clinical Site Torrance California 90502
Neurocrine Clinical Site Aventura Florida 33180
Neurocrine Clinical Site Coral Gables Florida 33134
Neurocrine Clinical Site Daytona Beach Florida 32114
Neurocrine Clinical Site Hialeah Florida 33012
Neurocrine Clinical Site Hialeah Florida 33013
Neurocrine Clinical Site Hialeah Florida 33016
Neurocrine Clinical Site Miami Florida 33133
Neurocrine Clinical Site Miami Florida 33137
Neurocrine Clinical Site Miami Florida 33144
Neurocrine Clinical Site Miami Lakes Florida 33016
Neurocrine Clinical Site Okeechobee Florida 34972
Neurocrine Clinical Site Tampa Florida 33629
Neurocrine Clinical Site West Palm Beach Florida 33407
Neurocrine Clinical Site Atlanta Georgia 30328
Neurocrine Clinical Site Evanston Illinois 60208
Neurocrine Clinical Site Springfield Illinois 62702
Neurocrine Clinical Site Grand Rapids Michigan 49503
Neurocrine Clinical Site St Louis Missouri 63125
Neurocrine Clinical Site St Louis Missouri 63128
Neurocrine Clinical Site Lincoln Nebraska 68526
Neurocrine Clinical Site Las Vegas Nevada 89102
Neurocrine Clinical Site Cedarhurst New York 11516
Neurocrine Clinical Sites Glen Oaks New York 11004
Neurocrine Clinical Site New York New York 10032
Neurocrine Clinical Site New York New York 10035
Neurocrine Clinical Site Charlotte North Carolina 28211
Neurocrine Clinical Site Dayton Ohio 45417
Neurocrine Clinical Site Oklahoma City Oklahoma 73112
Neurocrine Clinical Site Austin Texas 78754
Neurocrine Clinical Site Dallas Texas 75390
Neurocrine Clinical Site DeSoto Texas 75115
Neurocrine Clinical Site Houston Texas 77081
Neurocrine Clinical Site Houston Texas 77090

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05110157, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05110157 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →